Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2010-08-17

AUTHORS

A Santoro, T Pressiani, G Citterio, G Rossoni, G Donadoni, F Pozzi, L Rimassa, N Personeni, S Bozzarelli, G Rossoni, S Colombi, F G De Braud, F Caligaris-Cappio, A Lambiase, C Bordignon

ABSTRACT

BACKGROUND: Hepatocellular carcinoma (HCC) is a highly vascularised and poor-prognosis tumour. NGR-hTNF is a vascular-targeting agent consisting of human tumour necrosis factor-alpha fused to the tumour-homing peptide NGR, which is able to selectively bind an aminopeptidase N overexpressed on tumour blood vessels. METHODS: Twenty-seven patients with advanced-stage disease resistant to either locoregional (59%; range, 1-3), systemic treatments (52%; range, 1-3) or both (33%) received NGR-hTNF 0.8 microg m(-2) once every 3 weeks. The primary aim of the study was progression-free survival (PFS). RESULTS: No grade 3-4 treatment-related toxicities were noted. Common toxicity included mild-to-moderate, short-lived chills (63%). Median PFS was 2.3 months (95% CI: 1.7-2.9). A complete response ongoing after 20 months was observed in a sorafenib-refractory patient and a partial response in a Child-Pugh class-B patient, yielding a response rate of 7%. Six patients (22%) experienced stable disease. The disease control rate (DCR) was 30% and was maintained for a median PFS time of 4.3 months. Median survival was 8.9 months (95% CI: 7.5-10.2). In a subset of 12 sorafenib-resistant patients, the response rate was 8% and the median survival was 9.5 months. CONCLUSION: NGR-hTNF was well tolerated and showed single-agent activity in HCC. Further investigation in HCC is of interest. More... »

PAGES

837-844

Identifiers

URI

http://scigraph.springernature.com/pub.10.1038/sj.bjc.6605858

DOI

http://dx.doi.org/10.1038/sj.bjc.6605858

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1032128939

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/20717115


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Angiogenesis Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Carcinoma, Hepatocellular", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Liver Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neovascularization, Pathologic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Oligopeptides", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Tumor Necrosis Factor-alpha", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Oncology, Istituto Clinico Humanitas, Rozzano, Italy", 
          "id": "http://www.grid.ac/institutes/grid.417728.f", 
          "name": [
            "Department of Oncology, Istituto Clinico Humanitas, Rozzano, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Santoro", 
        "givenName": "A", 
        "id": "sg:person.013724631505.36", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013724631505.36"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Oncology, Istituto Clinico Humanitas, Rozzano, Italy", 
          "id": "http://www.grid.ac/institutes/grid.417728.f", 
          "name": [
            "Department of Oncology, Istituto Clinico Humanitas, Rozzano, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Pressiani", 
        "givenName": "T", 
        "id": "sg:person.01166652540.50", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01166652540.50"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Oncology, Istituto Scientifico San Raffaele, Milan, Italy", 
          "id": "http://www.grid.ac/institutes/grid.18887.3e", 
          "name": [
            "Department of Oncology, Istituto Scientifico San Raffaele, Milan, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Citterio", 
        "givenName": "G", 
        "id": "sg:person.01277273602.82", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01277273602.82"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Oncology, Istituto Scientifico San Raffaele, Milan, Italy", 
          "id": "http://www.grid.ac/institutes/grid.18887.3e", 
          "name": [
            "Department of Oncology, Istituto Scientifico San Raffaele, Milan, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Rossoni", 
        "givenName": "G", 
        "id": "sg:person.0627337550.70", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0627337550.70"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Oncology, Istituto Scientifico San Raffaele, Milan, Italy", 
          "id": "http://www.grid.ac/institutes/grid.18887.3e", 
          "name": [
            "Department of Oncology, Istituto Scientifico San Raffaele, Milan, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Donadoni", 
        "givenName": "G", 
        "id": "sg:person.01156617225.68", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01156617225.68"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Oncology, Istituto Scientifico San Raffaele, Milan, Italy", 
          "id": "http://www.grid.ac/institutes/grid.18887.3e", 
          "name": [
            "Department of Oncology, Istituto Scientifico San Raffaele, Milan, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Pozzi", 
        "givenName": "F", 
        "id": "sg:person.010773551223.60", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010773551223.60"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Oncology, Istituto Clinico Humanitas, Rozzano, Italy", 
          "id": "http://www.grid.ac/institutes/grid.417728.f", 
          "name": [
            "Department of Oncology, Istituto Clinico Humanitas, Rozzano, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Rimassa", 
        "givenName": "L", 
        "id": "sg:person.0733441746.71", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0733441746.71"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Oncology, Istituto Clinico Humanitas, Rozzano, Italy", 
          "id": "http://www.grid.ac/institutes/grid.417728.f", 
          "name": [
            "Department of Oncology, Istituto Clinico Humanitas, Rozzano, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Personeni", 
        "givenName": "N", 
        "id": "sg:person.01070711603.65", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01070711603.65"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Oncology, Istituto Clinico Humanitas, Rozzano, Italy", 
          "id": "http://www.grid.ac/institutes/grid.417728.f", 
          "name": [
            "Department of Oncology, Istituto Clinico Humanitas, Rozzano, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bozzarelli", 
        "givenName": "S", 
        "id": "sg:person.01137025003.82", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01137025003.82"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "MolMed, Milan, Italy", 
          "id": "http://www.grid.ac/institutes/grid.425866.b", 
          "name": [
            "MolMed, Milan, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Rossoni", 
        "givenName": "G", 
        "id": "sg:person.0630245173.19", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0630245173.19"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "MolMed, Milan, Italy", 
          "id": "http://www.grid.ac/institutes/grid.425866.b", 
          "name": [
            "MolMed, Milan, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Colombi", 
        "givenName": "S", 
        "id": "sg:person.01101160444.55", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01101160444.55"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Clinical Pharmacology and New Drugs, European Institute of Oncology, Milan, Italy", 
          "id": "http://www.grid.ac/institutes/grid.15667.33", 
          "name": [
            "Division of Clinical Pharmacology and New Drugs, European Institute of Oncology, Milan, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "De Braud", 
        "givenName": "F G", 
        "id": "sg:person.014263561244.29", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014263561244.29"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Universit\u00e0 Vita-Salute San Raffaele, Via Olgettina, Milan 20132, Italy", 
          "id": "http://www.grid.ac/institutes/grid.15496.3f", 
          "name": [
            "Department of Oncology, Istituto Scientifico San Raffaele, Milan, Italy", 
            "Universit\u00e0 Vita-Salute San Raffaele, Via Olgettina, Milan 20132, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Caligaris-Cappio", 
        "givenName": "F", 
        "id": "sg:person.01265553231.07", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01265553231.07"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "MolMed, Milan, Italy", 
          "id": "http://www.grid.ac/institutes/grid.425866.b", 
          "name": [
            "MolMed, Milan, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lambiase", 
        "givenName": "A", 
        "id": "sg:person.01026515661.63", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01026515661.63"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Universit\u00e0 Vita-Salute San Raffaele, Via Olgettina, Milan 20132, Italy", 
          "id": "http://www.grid.ac/institutes/grid.15496.3f", 
          "name": [
            "MolMed, Milan, Italy", 
            "Universit\u00e0 Vita-Salute San Raffaele, Via Olgettina, Milan 20132, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bordignon", 
        "givenName": "C", 
        "id": "sg:person.0672275501.40", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0672275501.40"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/81183", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004929050", 
          "https://doi.org/10.1038/81183"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.bjc.6604784", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052692843", 
          "https://doi.org/10.1038/sj.bjc.6604784"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.bjc.6605162", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027774281", 
          "https://doi.org/10.1038/sj.bjc.6605162"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2010-08-17", 
    "datePublishedReg": "2010-08-17", 
    "description": "BACKGROUND: Hepatocellular carcinoma (HCC) is a highly vascularised and poor-prognosis tumour. NGR-hTNF is a vascular-targeting agent consisting of human tumour necrosis factor-alpha fused to the tumour-homing peptide NGR, which is able to selectively bind an aminopeptidase N overexpressed on tumour blood vessels.\nMETHODS: Twenty-seven patients with advanced-stage disease resistant to either locoregional (59%; range, 1-3), systemic treatments (52%; range, 1-3) or both (33%) received NGR-hTNF 0.8 microg m(-2) once every 3 weeks. The primary aim of the study was progression-free survival (PFS).\nRESULTS: No grade 3-4 treatment-related toxicities were noted. Common toxicity included mild-to-moderate, short-lived chills (63%). Median PFS was 2.3 months (95% CI: 1.7-2.9). A complete response ongoing after 20 months was observed in a sorafenib-refractory patient and a partial response in a Child-Pugh class-B patient, yielding a response rate of 7%. Six patients (22%) experienced stable disease. The disease control rate (DCR) was 30% and was maintained for a median PFS time of 4.3 months. Median survival was 8.9 months (95% CI: 7.5-10.2). In a subset of 12 sorafenib-resistant patients, the response rate was 8% and the median survival was 9.5 months.\nCONCLUSION: NGR-hTNF was well tolerated and showed single-agent activity in HCC. Further investigation in HCC is of interest.", 
    "genre": "article", 
    "id": "sg:pub.10.1038/sj.bjc.6605858", 
    "inLanguage": "en", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1017082", 
        "issn": [
          "0007-0920", 
          "1532-1827"
        ], 
        "name": "British Journal of Cancer", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "6", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "103"
      }
    ], 
    "keywords": [
      "progression-free survival", 
      "disease control rate", 
      "NGR-hTNF", 
      "hepatocellular carcinoma", 
      "median survival", 
      "response rate", 
      "median progression-free survival", 
      "sorafenib-refractory patients", 
      "treatment-related toxicity", 
      "advanced stage disease", 
      "Child-Pugh class", 
      "median PFS time", 
      "single-agent activity", 
      "vascular-targeting agent", 
      "advanced hepatocellular carcinoma", 
      "poor prognosis tumors", 
      "human tumor necrosis", 
      "tumor blood vessels", 
      "common toxicities", 
      "stable disease", 
      "PFS time", 
      "systemic treatment", 
      "complete response", 
      "partial response", 
      "control rate", 
      "tumor necrosis", 
      "grade 3", 
      "patients", 
      "blood vessels", 
      "months", 
      "carcinoma", 
      "survival", 
      "primary aim", 
      "disease", 
      "further investigation", 
      "peptide NGR", 
      "aminopeptidase N", 
      "toxicity", 
      "tumors", 
      "agents", 
      "necrosis", 
      "mild", 
      "weeks", 
      "response", 
      "rate", 
      "treatment", 
      "chills", 
      "activity", 
      "NGR", 
      "vessels", 
      "safety", 
      "aim", 
      "subset", 
      "study", 
      "time", 
      "investigation", 
      "interest", 
      "class", 
      "tumour-homing peptide NGR", 
      "sorafenib-resistant patients", 
      "selective vascular-targeting agent"
    ], 
    "name": "Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma", 
    "pagination": "837-844", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1032128939"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1038/sj.bjc.6605858"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "20717115"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1038/sj.bjc.6605858", 
      "https://app.dimensions.ai/details/publication/pub.1032128939"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2021-11-01T18:15", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20211101/entities/gbq_results/article/article_522.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1038/sj.bjc.6605858"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/sj.bjc.6605858'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/sj.bjc.6605858'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/sj.bjc.6605858'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/sj.bjc.6605858'


 

This table displays all metadata directly associated to this object as RDF triples.

295 TRIPLES      22 PREDICATES      102 URIs      91 LITERALS      19 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1038/sj.bjc.6605858 schema:about N1ab96f187cbc490aaf1fe8c7e96cde01
2 N4acd946eb2ac48e5a2c967bd13358af1
3 N532588526ba14f19a38ae5ba112d6be5
4 N784a99b864de4a94960105b171a21f90
5 N8575927ea0204dcab4fa3eaeda4a3a11
6 N9f15400ec57c48a8b2cc9dcf7a9df39f
7 Nadd29107919146bcbcb4359cb6dd54fa
8 Nd50d18233f44407e8ce2b3515091f976
9 Nda4a02385aa9453e81a86b038fc13b09
10 Ndd6dc0277a794bb2a8794ac75739e5be
11 Ne5d8850bf6a549e59621ce30947531e8
12 Ne94d06570307419abe8f9ae6af0bfbb7
13 anzsrc-for:11
14 anzsrc-for:1112
15 schema:author Ne01a6075d4bb4f9788971bd2722eb571
16 schema:citation sg:pub.10.1038/81183
17 sg:pub.10.1038/sj.bjc.6604784
18 sg:pub.10.1038/sj.bjc.6605162
19 schema:datePublished 2010-08-17
20 schema:datePublishedReg 2010-08-17
21 schema:description BACKGROUND: Hepatocellular carcinoma (HCC) is a highly vascularised and poor-prognosis tumour. NGR-hTNF is a vascular-targeting agent consisting of human tumour necrosis factor-alpha fused to the tumour-homing peptide NGR, which is able to selectively bind an aminopeptidase N overexpressed on tumour blood vessels. METHODS: Twenty-seven patients with advanced-stage disease resistant to either locoregional (59%; range, 1-3), systemic treatments (52%; range, 1-3) or both (33%) received NGR-hTNF 0.8 microg m(-2) once every 3 weeks. The primary aim of the study was progression-free survival (PFS). RESULTS: No grade 3-4 treatment-related toxicities were noted. Common toxicity included mild-to-moderate, short-lived chills (63%). Median PFS was 2.3 months (95% CI: 1.7-2.9). A complete response ongoing after 20 months was observed in a sorafenib-refractory patient and a partial response in a Child-Pugh class-B patient, yielding a response rate of 7%. Six patients (22%) experienced stable disease. The disease control rate (DCR) was 30% and was maintained for a median PFS time of 4.3 months. Median survival was 8.9 months (95% CI: 7.5-10.2). In a subset of 12 sorafenib-resistant patients, the response rate was 8% and the median survival was 9.5 months. CONCLUSION: NGR-hTNF was well tolerated and showed single-agent activity in HCC. Further investigation in HCC is of interest.
22 schema:genre article
23 schema:inLanguage en
24 schema:isAccessibleForFree true
25 schema:isPartOf N3a9a9ee39483431c949ab8125221d750
26 Na849573b58b74bebbba829d6bf14e5a8
27 sg:journal.1017082
28 schema:keywords Child-Pugh class
29 NGR
30 NGR-hTNF
31 PFS time
32 activity
33 advanced hepatocellular carcinoma
34 advanced stage disease
35 agents
36 aim
37 aminopeptidase N
38 blood vessels
39 carcinoma
40 chills
41 class
42 common toxicities
43 complete response
44 control rate
45 disease
46 disease control rate
47 further investigation
48 grade 3
49 hepatocellular carcinoma
50 human tumor necrosis
51 interest
52 investigation
53 median PFS time
54 median progression-free survival
55 median survival
56 mild
57 months
58 necrosis
59 partial response
60 patients
61 peptide NGR
62 poor prognosis tumors
63 primary aim
64 progression-free survival
65 rate
66 response
67 response rate
68 safety
69 selective vascular-targeting agent
70 single-agent activity
71 sorafenib-refractory patients
72 sorafenib-resistant patients
73 stable disease
74 study
75 subset
76 survival
77 systemic treatment
78 time
79 toxicity
80 treatment
81 treatment-related toxicity
82 tumor blood vessels
83 tumor necrosis
84 tumors
85 tumour-homing peptide NGR
86 vascular-targeting agent
87 vessels
88 weeks
89 schema:name Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma
90 schema:pagination 837-844
91 schema:productId N320ed79a88d44c56835b89d535506312
92 Na924a4c1c0344d8fb6192850f909b181
93 Naf4e6dea4dc74c30b1a9a6046a5c10ee
94 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032128939
95 https://doi.org/10.1038/sj.bjc.6605858
96 schema:sdDatePublished 2021-11-01T18:15
97 schema:sdLicense https://scigraph.springernature.com/explorer/license/
98 schema:sdPublisher Nd1987e08f0fc41e7b7330ee2b8159930
99 schema:url https://doi.org/10.1038/sj.bjc.6605858
100 sgo:license sg:explorer/license/
101 sgo:sdDataset articles
102 rdf:type schema:ScholarlyArticle
103 N00b5595f9c2d46a79f1678ac1eae1600 rdf:first sg:person.0733441746.71
104 rdf:rest Ne069022c89734b51909d358dc6133f2e
105 N07918986a6da4c42a66ae1e31293bb9d rdf:first sg:person.010773551223.60
106 rdf:rest N00b5595f9c2d46a79f1678ac1eae1600
107 N0c5b2ec1ac504234831d3b52e7855109 rdf:first sg:person.0627337550.70
108 rdf:rest N1567f2780a90463783f40f43ca2fa296
109 N0dba5afd572d4c958751dbb764bfe037 rdf:first sg:person.01265553231.07
110 rdf:rest Nee7843f285ac4c39891d3af2d8020634
111 N1567f2780a90463783f40f43ca2fa296 rdf:first sg:person.01156617225.68
112 rdf:rest N07918986a6da4c42a66ae1e31293bb9d
113 N19c568305f7e4d28a701c53ac2a04332 rdf:first sg:person.01101160444.55
114 rdf:rest Na3f8f6ce007b4d7d8dd25480a4c1a917
115 N1ab96f187cbc490aaf1fe8c7e96cde01 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
116 schema:name Oligopeptides
117 rdf:type schema:DefinedTerm
118 N20fa3dae2a134a638536cb0d968d2f4f rdf:first sg:person.0630245173.19
119 rdf:rest N19c568305f7e4d28a701c53ac2a04332
120 N320ed79a88d44c56835b89d535506312 schema:name dimensions_id
121 schema:value pub.1032128939
122 rdf:type schema:PropertyValue
123 N3a9a9ee39483431c949ab8125221d750 schema:issueNumber 6
124 rdf:type schema:PublicationIssue
125 N4acd946eb2ac48e5a2c967bd13358af1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
126 schema:name Female
127 rdf:type schema:DefinedTerm
128 N532588526ba14f19a38ae5ba112d6be5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
129 schema:name Liver Neoplasms
130 rdf:type schema:DefinedTerm
131 N5ff6386a6ffb4dbab9294c0904e5be97 rdf:first sg:person.0672275501.40
132 rdf:rest rdf:nil
133 N784a99b864de4a94960105b171a21f90 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
134 schema:name Angiogenesis Inhibitors
135 rdf:type schema:DefinedTerm
136 N7e3b9270ab894656bb1cd7e7e0a1d907 rdf:first sg:person.01166652540.50
137 rdf:rest N88e3f2b5686e4e21a69564355f3a864f
138 N8575927ea0204dcab4fa3eaeda4a3a11 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
139 schema:name Neovascularization, Pathologic
140 rdf:type schema:DefinedTerm
141 N88e3f2b5686e4e21a69564355f3a864f rdf:first sg:person.01277273602.82
142 rdf:rest N0c5b2ec1ac504234831d3b52e7855109
143 N9f15400ec57c48a8b2cc9dcf7a9df39f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
144 schema:name Middle Aged
145 rdf:type schema:DefinedTerm
146 Na3f8f6ce007b4d7d8dd25480a4c1a917 rdf:first sg:person.014263561244.29
147 rdf:rest N0dba5afd572d4c958751dbb764bfe037
148 Na849573b58b74bebbba829d6bf14e5a8 schema:volumeNumber 103
149 rdf:type schema:PublicationVolume
150 Na924a4c1c0344d8fb6192850f909b181 schema:name doi
151 schema:value 10.1038/sj.bjc.6605858
152 rdf:type schema:PropertyValue
153 Nadd29107919146bcbcb4359cb6dd54fa schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
154 schema:name Carcinoma, Hepatocellular
155 rdf:type schema:DefinedTerm
156 Naf4e6dea4dc74c30b1a9a6046a5c10ee schema:name pubmed_id
157 schema:value 20717115
158 rdf:type schema:PropertyValue
159 Nd1987e08f0fc41e7b7330ee2b8159930 schema:name Springer Nature - SN SciGraph project
160 rdf:type schema:Organization
161 Nd50d18233f44407e8ce2b3515091f976 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
162 schema:name Aged
163 rdf:type schema:DefinedTerm
164 Nda4a02385aa9453e81a86b038fc13b09 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
165 schema:name Male
166 rdf:type schema:DefinedTerm
167 Ndd6dc0277a794bb2a8794ac75739e5be schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
168 schema:name Tumor Necrosis Factor-alpha
169 rdf:type schema:DefinedTerm
170 Ne01a6075d4bb4f9788971bd2722eb571 rdf:first sg:person.013724631505.36
171 rdf:rest N7e3b9270ab894656bb1cd7e7e0a1d907
172 Ne069022c89734b51909d358dc6133f2e rdf:first sg:person.01070711603.65
173 rdf:rest Nf095edc1181d49659bc9333f65c761d5
174 Ne5d8850bf6a549e59621ce30947531e8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
175 schema:name Humans
176 rdf:type schema:DefinedTerm
177 Ne94d06570307419abe8f9ae6af0bfbb7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
178 schema:name Adult
179 rdf:type schema:DefinedTerm
180 Nee7843f285ac4c39891d3af2d8020634 rdf:first sg:person.01026515661.63
181 rdf:rest N5ff6386a6ffb4dbab9294c0904e5be97
182 Nf095edc1181d49659bc9333f65c761d5 rdf:first sg:person.01137025003.82
183 rdf:rest N20fa3dae2a134a638536cb0d968d2f4f
184 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
185 schema:name Medical and Health Sciences
186 rdf:type schema:DefinedTerm
187 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
188 schema:name Oncology and Carcinogenesis
189 rdf:type schema:DefinedTerm
190 sg:journal.1017082 schema:issn 0007-0920
191 1532-1827
192 schema:name British Journal of Cancer
193 schema:publisher Springer Nature
194 rdf:type schema:Periodical
195 sg:person.01026515661.63 schema:affiliation grid-institutes:grid.425866.b
196 schema:familyName Lambiase
197 schema:givenName A
198 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01026515661.63
199 rdf:type schema:Person
200 sg:person.01070711603.65 schema:affiliation grid-institutes:grid.417728.f
201 schema:familyName Personeni
202 schema:givenName N
203 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01070711603.65
204 rdf:type schema:Person
205 sg:person.010773551223.60 schema:affiliation grid-institutes:grid.18887.3e
206 schema:familyName Pozzi
207 schema:givenName F
208 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010773551223.60
209 rdf:type schema:Person
210 sg:person.01101160444.55 schema:affiliation grid-institutes:grid.425866.b
211 schema:familyName Colombi
212 schema:givenName S
213 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01101160444.55
214 rdf:type schema:Person
215 sg:person.01137025003.82 schema:affiliation grid-institutes:grid.417728.f
216 schema:familyName Bozzarelli
217 schema:givenName S
218 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01137025003.82
219 rdf:type schema:Person
220 sg:person.01156617225.68 schema:affiliation grid-institutes:grid.18887.3e
221 schema:familyName Donadoni
222 schema:givenName G
223 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01156617225.68
224 rdf:type schema:Person
225 sg:person.01166652540.50 schema:affiliation grid-institutes:grid.417728.f
226 schema:familyName Pressiani
227 schema:givenName T
228 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01166652540.50
229 rdf:type schema:Person
230 sg:person.01265553231.07 schema:affiliation grid-institutes:grid.15496.3f
231 schema:familyName Caligaris-Cappio
232 schema:givenName F
233 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01265553231.07
234 rdf:type schema:Person
235 sg:person.01277273602.82 schema:affiliation grid-institutes:grid.18887.3e
236 schema:familyName Citterio
237 schema:givenName G
238 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01277273602.82
239 rdf:type schema:Person
240 sg:person.013724631505.36 schema:affiliation grid-institutes:grid.417728.f
241 schema:familyName Santoro
242 schema:givenName A
243 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013724631505.36
244 rdf:type schema:Person
245 sg:person.014263561244.29 schema:affiliation grid-institutes:grid.15667.33
246 schema:familyName De Braud
247 schema:givenName F G
248 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014263561244.29
249 rdf:type schema:Person
250 sg:person.0627337550.70 schema:affiliation grid-institutes:grid.18887.3e
251 schema:familyName Rossoni
252 schema:givenName G
253 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0627337550.70
254 rdf:type schema:Person
255 sg:person.0630245173.19 schema:affiliation grid-institutes:grid.425866.b
256 schema:familyName Rossoni
257 schema:givenName G
258 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0630245173.19
259 rdf:type schema:Person
260 sg:person.0672275501.40 schema:affiliation grid-institutes:grid.15496.3f
261 schema:familyName Bordignon
262 schema:givenName C
263 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0672275501.40
264 rdf:type schema:Person
265 sg:person.0733441746.71 schema:affiliation grid-institutes:grid.417728.f
266 schema:familyName Rimassa
267 schema:givenName L
268 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0733441746.71
269 rdf:type schema:Person
270 sg:pub.10.1038/81183 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004929050
271 https://doi.org/10.1038/81183
272 rdf:type schema:CreativeWork
273 sg:pub.10.1038/sj.bjc.6604784 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052692843
274 https://doi.org/10.1038/sj.bjc.6604784
275 rdf:type schema:CreativeWork
276 sg:pub.10.1038/sj.bjc.6605162 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027774281
277 https://doi.org/10.1038/sj.bjc.6605162
278 rdf:type schema:CreativeWork
279 grid-institutes:grid.15496.3f schema:alternateName Università Vita-Salute San Raffaele, Via Olgettina, Milan 20132, Italy
280 schema:name Department of Oncology, Istituto Scientifico San Raffaele, Milan, Italy
281 MolMed, Milan, Italy
282 Università Vita-Salute San Raffaele, Via Olgettina, Milan 20132, Italy
283 rdf:type schema:Organization
284 grid-institutes:grid.15667.33 schema:alternateName Division of Clinical Pharmacology and New Drugs, European Institute of Oncology, Milan, Italy
285 schema:name Division of Clinical Pharmacology and New Drugs, European Institute of Oncology, Milan, Italy
286 rdf:type schema:Organization
287 grid-institutes:grid.18887.3e schema:alternateName Department of Oncology, Istituto Scientifico San Raffaele, Milan, Italy
288 schema:name Department of Oncology, Istituto Scientifico San Raffaele, Milan, Italy
289 rdf:type schema:Organization
290 grid-institutes:grid.417728.f schema:alternateName Department of Oncology, Istituto Clinico Humanitas, Rozzano, Italy
291 schema:name Department of Oncology, Istituto Clinico Humanitas, Rozzano, Italy
292 rdf:type schema:Organization
293 grid-institutes:grid.425866.b schema:alternateName MolMed, Milan, Italy
294 schema:name MolMed, Milan, Italy
295 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...